Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK3/BTK-IN-7
CAS:<p>JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].</p>Formula:C29H30N8O4Color and Shape:SolidMolecular weight:554.6PP487
CAS:<p>PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].</p>Formula:C14H14BrN5OColor and Shape:SolidMolecular weight:348.2JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35FGFR-IN-5
CAS:<p>FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.</p>Formula:C25H22N6O3Color and Shape:SolidMolecular weight:454.48EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96Pyk2-IN-2
CAS:<p>Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].</p>Formula:C27H27N7OColor and Shape:SolidMolecular weight:465.55VEGFR-2-IN-12
<p>VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.</p>Formula:C22H24N6O3SColor and Shape:SolidMolecular weight:452.53CDDD11-8
CAS:<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Formula:C24H26N6Color and Shape:SolidMolecular weight:398.50EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formula:C28H23N7OColor and Shape:SolidMolecular weight:473.53VEGFR-2/DHFR-IN-1
<p>Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.</p>Formula:C20H18ClNO4Color and Shape:SolidMolecular weight:371.81FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Formula:C28H30N4O2Color and Shape:SolidMolecular weight:454.56DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColor and Shape:SolidMolecular weight:400.362MK-8457
CAS:<p>MK-8457 is a dual inhibitor of SYK and ZAP70, valuable for rheumatoid arthritis research [1].</p>Formula:C24H25F3N4O3SColor and Shape:SolidMolecular weight:506.54EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39VEGFR-2-IN-25
CAS:<p>VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).</p>Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formula:C30H29Cl2N7OColor and Shape:SolidMolecular weight:574.5Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58EG31
CAS:<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formula:C30H13Br2N3O6Color and Shape:SolidMolecular weight:671.25JAK/HDAC-IN-3
CAS:<p>JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].</p>Formula:C28H37FN6O5SColor and Shape:SolidMolecular weight:588.69Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64Tyk2-IN-14
CAS:<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42PNU-145156E
CAS:<p>PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.</p>Formula:C45H40N10O17S4Color and Shape:SolidMolecular weight:1121.12Lazertinib mesylate
CAS:<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Formula:C31H38N8O6SMolecular weight:650.75CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Formula:C30H32N6O4Color and Shape:SolidMolecular weight:540.61Ki11502
CAS:<p>Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.</p>Formula:C26H23N3O4SMolecular weight:473.54EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Formula:C18H21N5O3SColor and Shape:SolidMolecular weight:387.46FGFR4-IN-6
<p>FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.</p>Formula:C31H33N7O4Color and Shape:SolidMolecular weight:567.64FGFR4-IN-9
<p>FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.</p>Formula:C24H22ClF3N4O4Color and Shape:SolidMolecular weight:522.9EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formula:C27H31ClN7O3PColor and Shape:SolidMolecular weight:568.01E7090 succinate
CAS:<p>E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.</p>Formula:C76H92N10O24Color and Shape:SolidMolecular weight:1529.60Antiallergic agent-1
<p>Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.</p>Formula:C27H19F6N5OColor and Shape:SolidMolecular weight:543.46TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.50JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formula:C33H28N6O3SColor and Shape:SolidMolecular weight:588.68EGFR-IN-62
<p>EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.</p>Formula:C30H33N9O2Color and Shape:SolidMolecular weight:551.64PF-06463922 acetate
CAS:<p>PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.</p>Formula:C23H23FN6O4Color and Shape:SolidMolecular weight:466.46FGFR1 inhibitor-6
<p>FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.</p>Formula:C27H19N5O4S2Color and Shape:SolidMolecular weight:541.6ALK-IN-23
<p>ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.</p>Formula:C26H29ClN8O3SColor and Shape:SolidMolecular weight:569.08BTK-IN-10
CAS:<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Formula:C25H24F2N4O2Color and Shape:SolidMolecular weight:450.48VEGFR-2-IN-14
<p>VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Formula:C24H23N3O3SColor and Shape:SolidMolecular weight:433.52NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Formula:C25H29ClN6O5Purity:98%Color and Shape:SolidMolecular weight:528.99Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37
